These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

418 related articles for article (PubMed ID: 32861289)

  • 1. Allogeneic Transplantation and Chimeric Antigen Receptor-Engineered T-Cell Therapy for Relapsed or Refractory Mantle Cell Lymphoma.
    Gauthier J; Maloney DG
    Hematol Oncol Clin North Am; 2020 Oct; 34(5):957-970. PubMed ID: 32861289
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Is There Still a Role for Transplant for Patients with Mantle Cell Lymphoma (MCL) in the Era of CAR-T Cell Therapy?
    Beitinjaneh A; Kaufman A; Wang Y; Jain P; Srour SA; Wang M
    Curr Treat Options Oncol; 2022 Nov; 23(11):1614-1625. PubMed ID: 36227407
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cellular Therapies for Mantle Cell Lymphoma.
    Yassine F; Sandoval-Sus J; Ayala E; Chavez J; Hamadani M; Kharfan-Dabaja MA
    Transplant Cell Ther; 2021 May; 27(5):363-370. PubMed ID: 33965173
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mantle Cell Lymphoma: the Role of Risk-Adapted Therapy and Treatment of Relapsed Disease.
    Tarockoff M; Gonzalez T; Ivanov S; Sandoval-Sus J
    Curr Oncol Rep; 2022 Oct; 24(10):1313-1326. PubMed ID: 35639332
    [TBL] [Abstract][Full Text] [Related]  

  • 5. American Society of Transplantation and Cellular Therapy, Center of International Blood and Marrow Transplant Research, and European Society for Blood and Marrow Transplantation Clinical Practice Recommendations for Transplantation and Cellular Therapies in Mantle Cell Lymphoma.
    Munshi PN; Hamadani M; Kumar A; Dreger P; Friedberg JW; Dreyling M; Kahl B; Jerkeman M; Kharfan-Dabaja MA; Locke FL; Shadman M; Hill BT; Ahmed S; Herrera AF; Sauter CS; Bachanova V; Ghosh N; Lunning M; Kenkre VP; Aljurf M; Wang M; Maddocks KJ; Leonard JP; Kamdar M; Phillips T; Cashen AF; Inwards DJ; Sureda A; Cohen JB; Smith SM; Carlo-Stella C; Savani B; Robinson SP; Fenske TS
    Transplant Cell Ther; 2021 Sep; 27(9):720-728. PubMed ID: 34452722
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Current treatment strategies in relapsed/refractory mantle cell lymphoma: where are we now?
    Atilla E; Atilla PA; Demirer T
    Int J Hematol; 2017 Mar; 105(3):257-264. PubMed ID: 27995456
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impact of hematopoietic stem cell transplantation in patients with relapsed or refractory mantle cell lymphoma.
    Yamasaki S; Chihara D; Kim SW; Izutsu K; Iwato K; Fukuda T; Uchida N; Amano I; Nakazawa H; Kuroda J; Hashimoto H; Ichinohe T; Kanda Y; Atsuta Y; Suzumiya J; Suzuki R
    Ann Hematol; 2018 Aug; 97(8):1445-1452. PubMed ID: 29610968
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Exploring the Dilemma of Allogeneic Hematopoietic Cell Transplantation after Chimeric Antigen Receptor T Cell Therapy: To Transplant or Not?
    Bouziana S; Bouzianas D
    Biol Blood Marrow Transplant; 2020 Aug; 26(8):e183-e191. PubMed ID: 32304874
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Chimeric Antigen Receptor T Cell Therapy versus Hematopoietic Stem Cell Transplantation: An Evolving Perspective.
    Goldsmith SR; Ghobadi A; Dipersio JF; Hill B; Shadman M; Jain T
    Transplant Cell Ther; 2022 Nov; 28(11):727-736. PubMed ID: 35878743
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Chimeric antigen receptor T-cell therapy: a promising treatment modality for relapsed/refractory mantle cell lymphoma.
    Li P; Dong N; Zeng Y; Liu J; Tang X; Wang J; Zhang W; Ye S; Zhou L; Chang AH; Liang A
    Front Med; 2020 Dec; 14(6):811-815. PubMed ID: 32651937
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Experiences with Glofitamab Administration following CAR T Therapy in Patients with Relapsed Mantle Cell Lymphoma.
    Heini AD; Bacher U; Porret N; Wiedemann G; Legros M; Stalder Zeerleder D; Seipel K; Novak U; Daskalakis M; Pabst T
    Cells; 2022 Sep; 11(17):. PubMed ID: 36078155
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Allogeneic Stem Cell Transplantation and Chimeric Antigen Receptor (CAR) T-Cell Therapy for the Treatment of Non-Hodgkin Lymphoma.
    Hunter BD; Chen YB; Jacobson CA
    Hematol Oncol Clin North Am; 2019 Aug; 33(4):687-705. PubMed ID: 31229163
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Role of allogeneic stem cell transplantation in mantle cell lymphoma.
    Cohen JB; Burns LJ; Bachanova V
    Eur J Haematol; 2015 Apr; 94(4):290-7. PubMed ID: 25154430
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ibrutinib improves the efficacy of anti-CD19-CAR T-cell therapy in patients with refractory non-Hodgkin lymphoma.
    Liu M; Deng H; Mu J; Li Q; Pu Y; Jiang Y; Deng Q; Qian Z
    Cancer Sci; 2021 Jul; 112(7):2642-2651. PubMed ID: 33932067
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Controversies in lymphoma: the role of hematopoietic cell transplantation for mantle cell lymphoma and peripheral T cell lymphoma.
    Dreger P; Laport GG
    Biol Blood Marrow Transplant; 2008 Jan; 14(1 Suppl 1):100-7. PubMed ID: 18162229
    [TBL] [Abstract][Full Text] [Related]  

  • 16. How to Combine the Two Landmark Treatment Methods-Allogeneic Hematopoietic Stem Cell Transplantation and Chimeric Antigen Receptor T Cell Therapy Together to Cure High-Risk B Cell Acute Lymphoblastic Leukemia?
    Zhang M; Huang H
    Front Immunol; 2020; 11():611710. PubMed ID: 33384696
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sequencing of Novel Therapies for Mantle Cell Lymphoma.
    Romancik JT; Cohen JB
    Curr Treat Options Oncol; 2021 Nov; 22(12):118. PubMed ID: 34812968
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Third-generation anti-CD19 chimeric antigen receptor T-cells incorporating a TLR2 domain for relapsed or refractory B-cell lymphoma: a phase I clinical trial protocol (ENABLE).
    George P; Dasyam N; Giunti G; Mester B; Bauer E; Andrews B; Perera T; Ostapowicz T; Frampton C; Li P; Ritchie D; Bollard CM; Hermans IF; Weinkove R
    BMJ Open; 2020 Feb; 10(2):e034629. PubMed ID: 32041862
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Relapsed primary central nervous system lymphoma treated with CD19 chimeric antigen receptor T-cell therapy and allogeneic hematopoietic stem cell transplantation].
    Fujii F; Terao T; Nishimori H; Fujii K; Matsuo T; Yoshino T; Ueda H; Oyama T; Matsumura A; Kondo K; Matsubara C; Fujiwara K; Seike K; Fujiwara H; Asada N; Ennishi D; Fujii K; Fujii N; Matsuoka KI; Maeda Y
    Rinsho Ketsueki; 2024; 65(7):622-627. PubMed ID: 39098011
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Long-term sustained disease control in patients with mantle cell lymphoma with or without active disease after treatment with allogeneic hematopoietic cell transplantation after nonmyeloablative conditioning.
    Vaughn JE; Sorror ML; Storer BE; Chauncey TR; Pulsipher MA; Maziarz RT; Maris MB; Hari P; Laport GG; Franke GN; Agura ED; Langston AA; Rezvani AR; Storb R; Sandmaier BM; Maloney DG
    Cancer; 2015 Oct; 121(20):3709-16. PubMed ID: 26207349
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.